Emel Akkaya

Learn More
Anthracyclin-based regimens and all-transretinoic acid (ATRA, tretinoin) as differentiating agent are commonly utilized for the treatment of acute promylelocytic leukemia (APL). There are many adverse effects that may be seen during the use of ATRA in patients with APL. Of these, ATRA-induced myositis is rarely described in adults and rare in the children(More)
BACKGROUND Despite the presence of reports on correlation between major congenital defects and cancer, very few studies have investigated the frequency of minor anomalies in childhood malignancy. The aim of this study was to determine the prevalence of minor anomalies in children with hematological malignancy. PROCEDURE A total of 62 well-defined minor(More)
Janus kinase 2 (JAK2) is a protein tyrosine kinase that transduces cellular signals through the Janus kinase signal transducer and an activator of transcription pathways (JAK-STAT), which mediates cell growth, differentiation, apoptosis, transformation, and other fundamental cell functions, and is active in both normal hematopoiesis and hematological(More)
Older patients with acute myeloid leukemia (AML) have dismal outcomes. Molecular genetic aberrations offer the possibility to define patients that may benefit from standard chemotherapy and to identify targets for novel treatment approaches. Introduction The median age at diagnosis of AML in industrialized countries is 6572 years, and it is likely(More)
  • 1